Daniel Yip, WG’08 is currently the Head of U.S. Marketing at Intercept Pharmaceuticals, a biopharmaceutical company focused on developing innovative therapies for non-viral chronic liver diseases. He currently leads the US marketing efforts for the potential commercial launch of a drug for a rare liver disorder called primary biliary cirrhosis. He was previously Director of Business Operations at Amicus Therapeutics, where his responsibilities included commercial and business development, strategic planning, and program management. Prior to Amicus, Daniel was a key member of the Rituxan brand team at Genentech where he launched the product for the treatment of rheumatoid arthritis. Before Genentech, Daniel spent several years in sales at GlaxoSmithkline where he launched Advair Diskus for asthma. Daniel received his M.B.A. from Wharton with a concentration in Healthcare Management. He received his B.A. in Molecular and Cell Biology and M.P.H. in Health Policy and Management from the University of California, Berkeley. He currently lives and works in New York City.

Sam has more than a decade of drug development and commercialization experience in the pharmaceutical, academic, and biotech worlds. Prior to joining Cambridge BioMarketing he worked at the Publicis Groupe, where he led scientific strategy on multiple antiviral products as well as groundbreaking investigational oncology therapies. While in academic drug discovery, Sam was part of a research team that developed and successfully licensed 3 oncology agents, including a first-in-class targeted oncology therapy currently in phase I clinical trials. Sam has helped develop the scientific and clinical strategies and narratives for at least a dozen rare diseases and orphan products. His expertise is complemented by the clinical department of PhDs and MDs that he and CB have cultivated. In addition to his work at CB Sam is a member of a data monitoring committee for the NCI Community Clinical Oncology Program and has served as President of a chapter of the American Medical Writers Association.

QUALIFICATIONS
Director of Medical Strategy @ Cambridge BioMarketing August 2012 – Present Data Monitoring Committee Member @ National Cancer Institute Community Clinical Oncology Program May 2008 – Present Clinical Science Director @ Cambridge BioMarketing January 2011 – August 2012 Scientific Director @ Discovery Chicago October 2010 – January 2011

PRIOR SPEAKING EXPERIENCE
Regular speaker at medical institutions to help clinicians transition into commercial roles. Also a facilitator at advisory board meetings with both healthcare professionals and patient groups.

DIVERSITY
Sam brings an unique perspective of clinical understanding to the conversations. His years in experience with orphan and ultra-orphan disease give him the ability to speak from not only a medical standpoint but also from the practicing physician's point of view